Researchers find novel approach for controlling deadly C. difficile infections

Jan 30, 2014
Kenneth Kai-Sing Ng, right, an associate professor in biochemistry, and Tomohiko Murase, a research associate, have made new advances for the detection and treatment of Clostridium difficile. Photo by Riley Brandt, University of Calgary. Credit: Riley Brandt, University of Calgary

Researchers from the Alberta Glycomics Centre at the University of Calgary and the University of Alberta, in collaboration with researchers at the National Research Council of Canada in Ottawa, have revealed the first molecular views showing how highly specific antibodies derived from llamas may provide a new method for controlling deadly infections from the opportunistic bacterial pathogen Clostridium difficile (C. difficile).

Published in the Journal of Biological Chemistry, the research reveals for the first time how recognize the disease's two central toxin proteins – toxin A (TcdA) and toxin B (TcdB).

This new information provides exciting opportunities for creating a new generation of engineered antibodies that will be more effective at preventing the toxins from damaging the intestine during the normal course of the disease.

"Our research is an important step towards developing highly specific ways to treat this very common and serious disease," says Kenneth Ng, associate professor in the Department of Biological Sciences at the University of Calgary and the study's senior author.

C. difficile causes one of the most common and problematic hospital-acquired infections worldwide. The infection is primarily transmitted within healthcare facilities, and causes extreme diarrhea and potentially fatal colon inflammation.

A Canadian hospital study found that of 136,877 hospital admissions, 1 in 100 patients will contract C. difficile infection, and of those, 1 in 10 will die regardless of the initial reasons for admission. The disease is most frequently seen in older adults who take antibiotics and get medical care. Annual healthcare costs are estimated to be several billion dollars worldwide.

The key findings in the paper derive from the three-dimensional structures of antibody-toxin complexes that were determined using X-ray crystallography by Tomohiko Murase, Luiz Eugenio and Melissa Schorr in Dr. Ng's laboratory.

The antibody-toxin complexes were developed using single-domain antibodies derived from llamas.

"The smaller size of the llama antibodies compared to the currently used for diagnostics or in development for therapeutics greatly assists with structure determination and protein engineering," explains Ng. "Starting from these structures, we are now creating modified antibodies for improving treatments in the future."

"Basic biological research on llamas, camels and sharks led to the discovery of a smaller type of antibody with a simpler structure," adds Ng. "It is this simpler structure that allows us to make modifications and perform many detailed studies that are not easily done with other types of antibodies.

The unique characteristics of these single-domain antibodies provide an attractive approach for developing new treatments for C. difficile."

According to Ng, although the research is at the fundamental science level, the new structures provide a blueprint for designing new molecules that could neutralize the bacterial toxins more effectively than anything currently available.

This project relied on important contributions from Elena Kitova in John Klassen's mass spectrometry group at the Alberta Glycomics Centre, at the University of Alberta, as well as from Greg Hussack in Jamshid Tanha's antibody therapeutics group at the National Research Council in Ottawa.

Explore further: Engineered anti-toxin antibodies improve efficacy

More information: www.jbc.org/content/289/4/2331.abstract

add to favorites email to friend print save as pdf

Related Stories

Engineered anti-toxin antibodies improve efficacy

Jan 09, 2014

The effectiveness of toxin-neutralizing antibodies is considered to be mediated through the interaction of the variable region of the antibody and the toxin; however, recent studies suggest that the constant region (Fc) of ...

Antibody builders

Nov 19, 2013

Antibodies are often the first line of defense against the body's invaders.  Built to recognize and attack foreign bacteria and viruses, antibody molecules are released by cells to do battle with microbial ...

C. difficile lengthens hospital stays by 6 days

Dec 05, 2011

A new study published in the CMAJ (Canadian Medical Association Journal) reports that hospital-acquired Clostridium difficile infection increases length of stay in hospital by an average of six days.

Bacteriophages battle superbugs

Jul 18, 2013

IFR microbiologists are reinvigorating a way of battling C. difficile infections that they hope will help overcome the growing problem of antibiotic resistant superbugs in hospitals.

Recommended for you

World's first successful visualisation of key coenzyme

4 minutes ago

Japanese researchers have successfully developed the world's first imaging method for visualising the behaviour of nicotine-adenine dinucleotide derivative (NAD(P)H), a key coenzyme, inside cells. This feat ...

User comments : 0

More news stories

A beautiful, peculiar molecule

"Carbon is peculiar," said Nobel laureate Sir Harold Kroto. "More peculiar than you think." He was speaking to a standing-room-only audience that filled the Raytheon Amphitheater on Monday afternoon for the ...

Melting during cooling period

(Phys.org) —A University of Maine research team says stratification of the North Atlantic Ocean contributed to summer warming and glacial melting in Scotland during the period recognized for abrupt cooling ...